Allergy Therapeutics plc will have to conduct a new U.S. trial of its hay fever allergy vaccine at an additional cost of £10 million (US$20.3 million) after one subject suffered an adverse reaction, causing the FDA to put the trial on hold. This also will delay the launch of the product by 12 months. (BioWorld International)

Vivus Inc. won FDA approval of its Evamist product, triggering a $140 million milestone payment from a partnership entered earlier this year. (BioWorld Today)